Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATES trial of maintenance thalidomide after pemetrexed-based chemotherapy in unresectable malignant mesothelioma
ACTRN12609000141246Phase 3Completed
- Sponsor
- University of Sydney
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mesothelioma, pleural mesothelioma and peritoneal mesothelioma comparing Maintenance thalidomide with Observation after first-line chemotherapy (2 arms). Primary endpoint: Quality of life. Started May 2009; status: completed.
02
Drugs
thalidomide
03
Conditions
mesotheliomapleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on ACTRN12609000141246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000141246.